386 related articles for article (PubMed ID: 34437720)
21. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
De Corso E; Pasquini E; Trimarchi M; La Mantia I; Pagella F; Ottaviano G; Garzaro M; Pipolo C; Torretta S; Seccia V; Cantone E; Ciofalo A; Lucidi D; Fadda GL; Pafundi PC; Settimi S; Montuori C; Anastasi F; Pagliuca G; Ghidini A; Cavaliere C; Maffei M; Bussu F; Gallo S; Canevari FRM; Paludetti G; Galli J;
Allergy; 2023 Oct; 78(10):2669-2683. PubMed ID: 37203259
[TBL] [Abstract][Full Text] [Related]
22. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
Mullol J; Lund VJ; Wagenmann M; Han JK; Sousa AN; Smith SG; Mayer B; Chan RH; Fokkens WJ
Rhinology; 2024 Jun; 62(3):320-329. PubMed ID: 38217844
[TBL] [Abstract][Full Text] [Related]
23. Doxycycline Improves Quality of Life and Anosmia in Chronic Rhinosinusitis With Nasal Polyposis: A Randomized Controlled Trial.
Nabavi M; Arshi S; Bemanian MH; Fallahpour M; Shokri S; Sabouri S; Moosavian F; Nazari J; Bakrani V; Atashrazm F
Am J Rhinol Allergy; 2023 Jul; 37(4):384-390. PubMed ID: 36740870
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
[TBL] [Abstract][Full Text] [Related]
25. Individual SNOT-22 Items Aid in Differentiating Between Spontaneous Cerebrospinal Fluid Rhinorrhea and Chronic Rhinosinusitis Without Nasal Polyps.
Liu MY; Gardner JR; Woodworth BA; Jang DW; Kanaan A; Radabaugh JP; Yao WC; Goros M; Challa M; Grayson JW; Wang Z; Chen PG
Ann Otol Rhinol Laryngol; 2023 Jun; 132(6):698-704. PubMed ID: 35833241
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
27. Psychometric validity of the 22-item Sinonasal Outcome Test.
Hopkins C; Gillett S; Slack R; Lund VJ; Browne JP
Clin Otolaryngol; 2009 Oct; 34(5):447-54. PubMed ID: 19793277
[TBL] [Abstract][Full Text] [Related]
28. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.
Sindwani R; Han JK; Soteres DF; Messina JC; Carothers JL; Mahmoud RA; Djupesland PG
Am J Rhinol Allergy; 2019 Jan; 33(1):69-82. PubMed ID: 30477309
[TBL] [Abstract][Full Text] [Related]
29. 5-Item sino-nasal outcome test and 22-item sino-nasal outcome test relationship with endoscopic and radiologic scores in chronic rhinosinusitis with nasal polyps.
Misirovs R; Chan R; Lipworth B
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):363-367. PubMed ID: 37984707
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis.
Fokkens W; Van Der Lans R; Reitsma S
Expert Opin Biol Ther; 2021 May; 21(5):575-585. PubMed ID: 33724109
[No Abstract] [Full Text] [Related]
31. Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study.
Giombi F; Pace GM; Nappi E; Giunta G; Muci G; Pirola F; Ferreli F; Heffler E; Paoletti G; Giannitto C; Mercante G; Francone M; Spriano G; Canonica GW; Malvezzi L
Laryngoscope; 2024 Jun; 134(6):2626-2633. PubMed ID: 38126613
[TBL] [Abstract][Full Text] [Related]
32. Differences in the Sino-Nasal Outcome Test 22 and visual analog scale symptom scores in chronic rhinosinusitis with and without nasal polyps.
Gregurić T; Trkulja V; Baudoin T; Grgić M; Šmigovec I; Kalogjera L
Am J Rhinol Allergy; 2016; 30(2):107-12. PubMed ID: 26980391
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.
Galletti C; Ciodaro F; Barbieri MA; Gambino F; Ferrisi MG; Portelli D; Catalano N; Spina E; Freni F; Galletti B
Am J Otolaryngol; 2024; 45(4):104329. PubMed ID: 38696895
[TBL] [Abstract][Full Text] [Related]
34. Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study.
Hopkins C; Buchheit KM; Heffler E; Cohen NA; Olze H; Khan AH; Msihid J; Siddiqui S; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2022; 15():767-773. PubMed ID: 35698581
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
37. Reduced sinonasal levels of 1α-hydroxylase are associated with worse quality of life in chronic rhinosinusitis with nasal polyps.
Schlosser RJ; Carroll WW; Soler ZM; Pasquini WN; Mulligan JK
Int Forum Allergy Rhinol; 2016 Jan; 6(1):58-65. PubMed ID: 26575398
[TBL] [Abstract][Full Text] [Related]
38. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
[TBL] [Abstract][Full Text] [Related]
39. The SNOT-22 factorial structure in European patients with chronic rhinosinusitis: new clinical insights.
Dejaco D; Riedl D; Huber A; Moschen R; Giotakis AI; Bektic-Tadic L; Steinbichler T; Kahler P; Riechelmann H
Eur Arch Otorhinolaryngol; 2019 May; 276(5):1355-1365. PubMed ID: 30739177
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
